Agreement between an in‐house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to <scp>HIV</scp>‐1 protease, reverse transcriptase, and integrase inhibitors
Francesco Saladini(University of Siena), Maurizio Zazzi(University of Siena)
Cited by 26
Related Papers
New findings in HCV genotype distribution in selected West European, Russian and Israeli regions
|Journal of Clinical Virology|2016|73
Inflammation burden score in multidrug-resistant HIV-1 infection
|Journal of Infection|2023|8
Polypharmacy, anticholinergic burden and drug–drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry
|Journal of Antimicrobial Chemotherapy|2024|7
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry
|International Journal of Antimicrobial Agents|2023|6